Here are three things to know.
1. Lokelma is intended to treat patients with hyperkalemia, a condition involving elevated potassium levels in the blood.
2. AstraZeneca gained the rights to the drug through its $2.7 billion acquisition of ZS Pharma in 2015, according to Reuters.
3. Lokelma will compete with Vifor Pharma’s drug Veltassa, also used to treat hyperkalemia.
More articles on supply chain:
Vermont first state to legalize drug importation from Canada
6 key proposals unveiled in Trump’s plan to combat rising drug costs
62% of hospital leaders support Amazon as a medical supplier
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
